Literature DB >> 35118116

Lung Adenocarcinoma Cells Promote Self-Migration and Self-Invasion by Activating Neutrophils to Upregulate Notch3 Expression of Cancer Cells.

Weidong Peng1,2, Youjing Sheng1,2, Han Xiao1, Yuanzi Ye1, Louis Boafo Kwantwi2, Lanqing Cheng3, Yuanchong Wang4, Jiegou Xu5, Qiang Wu1,2.   

Abstract

Background: Invasion and migration of cancer cells play a key role in lung cancer progression and metastasis. Tumor-associated neutrophils (TANs) are related to poor prognosis in many types of cancer. However, the role of TANs in lung cancer is controversial. In this study, we investigated the effect of TANs on the invasion and migration of lung adenocarcinoma.
Methods: Immunohistochemistry was performed to detect the density of infiltrating TANs and the expression of Notch3 in 100 lung adenocarcinoma tissues. Flow cytometry was used to observe the viability of neutrophils, which were isolated from healthy peripheral blood and then exposed to the supernatant of cultured lung adenocarcinoma cell lines. After treating with tumor-associated neutrophils culture supernatant, NeuCS (supernatant of cultured neutrophils), tumor cells culture supernatant, Medium (serum-free medium), respectively, the migration and invasion of the lung cancer cells before and after transfected by si-Notch3 were detected by transwell assay and wound healing assay. Kaplan-Meier plotter (http://kmplot.com/analysis/index.php?p) was used to analyze the prognostic role of the density of TANs on lung adenocarcinoma and TIMER ((http://cistrome.dfci.harvard.edu/TIMER/) was used to detect the expression of Notch3 on lung adenocarcinoma.
Results: The infiltration of TANs was observed in the parenchyma and stroma of the lung adenocarcinoma, the density of TANs was positively related to the TNM stage and negatively related to the differentiation and prognosis. Notch3 expression of cancer cells was negatively related to the tumor differentiation and prognosis. Compared to quiescent neutrophils, the viability of TCCS-activated neutrophils was enhanced. Both migration and invasion of A549 and PC9 cells were significantly promoted by TANs, while after knocking down Notch3, the migration and invasion of the cancer cells were not affected by TANs. Bioinformatics analysis showed that the density of TANs and the expression of Notch3 were related to the poor prognosis.
Conclusion: The results indicated that lung adenocarcinoma cells promote self-invasion and self-migration by activating neutrophils to upregulate the Notch3 expression of cancer cells. The density of infiltrating TANs may be a novel marker for the poor prognosis of lung adenocarcinoma. Targeting TANs might be a potential therapeutic strategy for lung cancer treatment.
Copyright © 2022 Peng, Sheng, Xiao, Ye, Kwantwi, Cheng, Wang, Xu and Wu.

Entities:  

Keywords:  Notch3; invasion; lung adenocarcinoma; migration; tumor-associated neutrophils

Year:  2022        PMID: 35118116      PMCID: PMC8804382          DOI: 10.3389/fmolb.2021.762729

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  30 in total

Review 1.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Neutrophils, G-CSF and their contribution to breast cancer metastasis.

Authors:  Kellie A Mouchemore; Robin L Anderson; John A Hamilton
Journal:  FEBS J       Date:  2017-09-21       Impact factor: 5.542

Review 3.  Notch Signaling in Mammalian Intestinal Stem Cells: Determining Cell Fate and Maintaining Homeostasis.

Authors:  Shao-Jie Liang; Xiang-Guang Li; Xiu-Qi Wang
Journal:  Curr Stem Cell Res Ther       Date:  2019       Impact factor: 3.828

4.  Breast cancer cells promote self-migration by secreting interleukin 8 to induce NET formation.

Authors:  Zeyu Cai; Mingxun Zhang; Louis Boafo Kwantwi; Xiaomin Bi; Chenchen Zhang; Zhongle Cheng; Xiaojuan Ding; Tianhong Su; Hua Wang; Qiang Wu
Journal:  Gene       Date:  2020-06-13       Impact factor: 3.688

5.  Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Nikhil T Sebastian; Rohit Raj; Rahul Prasad; Christian Barney; Jeremy Brownstein; John Grecula; Karl Haglund; Meng Xu-Welliver; Terence M Williams; Jose G Bazan
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

Review 6.  Lung cancer: current therapies and new targeted treatments.

Authors:  Fred R Hirsch; Giorgio V Scagliotti; James L Mulshine; Regina Kwon; Walter J Curran; Yi-Long Wu; Luis Paz-Ares
Journal:  Lancet       Date:  2016-08-27       Impact factor: 79.321

7.  Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor.

Authors:  Wu-Hu Zhang; Wen-Quan Wang; He-Li Gao; Shuai-Shuai Xu; Shuo Li; Tian-Jiao Li; Xuan Han; Hua-Xiang Xu; Hao Li; Wang Jiang; Long-Yun Ye; Xuan Lin; Chun-Tao Wu; Xian-Jun Yu; Liang Liu
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

8.  Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer.

Authors:  Yuan-zi Ye; Zhi-hong Zhang; Xiao-yun Fan; Xiao-lan Xu; Mei-li Chen; Bo-wen Chang; Yan-bei Zhang
Journal:  Med Oncol       Date:  2013-05-07       Impact factor: 3.064

9.  Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.

Authors:  X Yan; S-C Jiao; G-Q Zhang; Y Guan; J-L Wang
Journal:  Cancer Gene Ther       Date:  2017-01-13       Impact factor: 5.987

10.  Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.

Authors:  Mariaelena Capone; Diana Giannarelli; Domenico Mallardo; Gabriele Madonna; Lucia Festino; Antonio Maria Grimaldi; Vito Vanella; Ester Simeone; Miriam Paone; Giuseppe Palmieri; Ernesta Cavalcanti; Corrado Caracò; Paolo Antonio Ascierto
Journal:  J Immunother Cancer       Date:  2018-07-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.